MedTrace Logo

Effect of Early Compression and Exercise on Lymphedema Incidence in Patients With Gynecological Cancer

NCT02966327 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-02-25

No results posted yet for this study

Summary

Objectives: 1) To evaluate the effect of early compression therapy with individualized exercise on the incidence of lower limb lymphedema at 12 months post-operatively in patients treated for gynecological cancer who are at risk of developing lymphedema; 2) To evaluate the effect of early compression therapy with individualized exercise on lower limb volume, quality of life and incidence of cellulitis infections at 12 months post-operatively in this population.

Conditions

  • Genital Neoplasms, Female
  • Lymphedema

Interventions

DEVICE

Bilateral leg compression stockings

Prescribed Jobst Elvarex compression class 1 (18 to 21 mmHg) standard or custom-made stockings for both lower limbs with or without panty; participants will be recommended to wear the garments for 12 to 16 hours daily for at least 6 months post-operatively.

BEHAVIORAL

Individualized exercise

Individualized education on exercise according to the Canadian Physical Activity Guidelines and self-lymphatic drainage techniques

BEHAVIORAL

Lymphedema risk reduction

Standard education on lymphedema risk reduction along with printed materials from the Lymphedema Association of Quebec

Sponsors & Collaborators

  • Jewish General Hospital

    collaborator OTHER

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    lead OTHER

Principal Investigators

  • Shirin M. Shallwani, MSc, PT · McGill University Health Centre/Research Institute of the McGill University Health Centre

  • Anna Towers, MD · McGill University Health Centre/Research Institute of the McGill University Health Centre

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-01
Primary Completion
2019-04-30
Completion
2019-10-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02966327 on ClinicalTrials.gov